Ocular Therapeutix (OCUL) plans to advance AXPAXLI in non-proliferative diabetic retinopathy, NPDR, and the Company’s strategic outlook for 2025 in its presentation at the 43rd Annual J.P. Morgan Healthcare Conference. 311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular’s second registrational trial of AXPAXLI in wet AMD, as of January 10, 2024; First wet AMD registrational trial, SOL-1, completed randomization in December 2024 with topline data anticipated in Q4 2025; Company plans to seek FDA feedback in H1 2025 on clinical trial design for AXPAXLI in NPDR.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- EyePoint initiated with a Buy at Citi
- Ocular Therapeutix reports inducement grant under Nasdaq listing rule
- Ocular Therapeutix announces over 300 subjects randomized in SOL-1
- Ocular Therapeutix price target raised to $15 from $14 at H.C. Wainwright
- Ocular Therapeutix Reports Q3 2024 Financial Results